Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Roy S. Herbst(Smilow Cancer Hospital), Chong‐Jen Yu(National Taiwan University Hospital), Yuri Rukazenkov(Chinese University of Hong Kong), Jonathan W. Goldman(University of California, Los Angeles), Masahiro Tsuboi(National Cancer Center Hospital East), Sang‐We Kim(Ulsan College), Rachel Hodge(GlaxoSmithKline (United Kingdom)), Margarita Majem(Chinese Academy of Medical Sciences & Peking Union Medical College), Laura Bonanno(Louisiana State University), Kye Young Lee(Konkuk University Medical Center), Frances A. Shepherd(University Health Network), К. К. Лактионов(Russian Cancer Research Center NN Blokhin), Charuwan Akewanlop(Siriraj Hospital), Manuel Dómine(Chinese Academy of Medical Sciences & Peking Union Medical College), Thomas John(Austin Hospital), Terufumi Kato(Taipei Veterans General Hospital), Jie He(Chinese Academy of Medical Sciences & Peking Union Medical College), Huu-Vinh Vu(Chinese Academy of Medical Sciences & Peking Union Medical College), Ajlan Atasoy(Chinese Academy of Medical Sciences & Peking Union Medical College), Lingmin Zeng(Chinese Academy of Medical Sciences & Peking Union Medical College), Filippo de Marinis(Carlo Forlanini Hospital), Christian Grohé(DRK Kliniken Berlin), Shun Lü(Shanghai Jiao Tong University)
Cited by 1,747
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k